

## Special Issue

# Neuroblastoma: Molecular Insights and Clinical Implications

### Message from the Guest Editor

Neuroblastoma has long frustrated clinicians as it is a very heterogeneous, oftentimes aggressive cancer of childhood. It is the most common non-brain solid tumor in children, and the survival remains under 70% for most patients. Therefore, physician scientists as well as bench scientists have long sought to understand this disease in order to find better targeted therapies. The articles in this issue will focus on some of the newer treatment modalities that go beyond traditional chemotherapies and include immunotherapies and small molecule therapies. This issue is dedicated to showcasing some of the most up-to-date developments in the field. The hope is that by understanding the molecular mechanisms of neuroblastoma, we will find new targets for therapy and improve survival in children with this tumor.

---

### Guest Editor

Dr. Mary Beth Madonna

Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL 60612, USA

---

### Deadline for manuscript submissions

30 April 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/185329](https://mdpi.com/si/185329)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)